The company was founded in March 1951 and listed on the Shanghai Stock Exchange in December 2000. The company has deep professional pharmaceutical experience, and is a national key high-tech enterprise and one of the top 100 enterprises in China's pharmaceutical industry. Relying on Yunnan's rich plant resources, Kunyao Group has successively developed more than 40 new natural medicine products with advanced standards at home and abroad, including three series of artemisia, 37, and Tianma, specialty traditional Chinese medicine, and ethnic medicine. At the same time, inheriting the essence of Chinese medicine, it has created a number of fine Chinese medicines represented by Shenling, Spleen, Stomach, and Liver Relief Granules, etc., gradually forming the four core business patterns of chronic disease management, health consumption, overseas international, and beautiful health. The industry in which the company is located is pharmaceutical manufacturing. The business area covers the entire pharmaceutical industry chain. The core business covers pharmaceutical R&D, production and sales, pharmaceutical distribution, and the health industry. The business development is based on mainland China and is actively deployed globally. The company's core products include Kunyao Xuesetong series, Tianmarin series, artemether series, Shenling, Spleen and Stomach Granules, Shu Lian Granules, Fragrant Sand Calming Granules, Sodium Hyaluronate Injection, Alfacalcidol Softgels, and Caoxalcin Softgels. The company was selected as a “National Technological Innovation Demonstration Enterprise” by the Ministry of Industry and Information Technology, the “2019 Top 100 Chinese Pharmaceutical Innovative Enterprises”, “Top 500 Chinese Enterprise Patents”, and “2022 Brand with the Highest Recommendation Rate for Chinese Pharmacy Clerk” by the China Pharmaceutical Enterprise Management Association.